Company Profile

Adecto Pharmaceuticals Inc
Profile last edited on: 2/6/2020      CAGE: 77W28      UEI: DAR5SR7BVBB6

Business Identifier: Novel targeted treatments for patients with highly aggressive cancerss.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

75 Kneeland Street 14th Floor
Boston, MA 02111
   (617) 794-4979
Location: Single
Congr. District: 07
County: Suffolk

Public Profile

Structured around developing novel targeted treatments for patients with highly aggressive cancers, the first product in the Adecto Pharmaceutical pipeline is an antibody-based therapy for triple-negative breast cancers. Originally workng at Tufts, principals of the firm organzied developing an antibodies, against the specific protein ADAM, for the treatment of Triple Negative Breast Cancer (TNBC) and metastatic breast cancer as the initial indications.TNBC represents a portion of breast tumor cases but is highly metastatic and accounts for more than half of the breast cancer deaths yearly worldwide. The ADAM8 protein is expressed on the cancer cell surface, downstream of the NF-?B family of transcription factors known to promote resistance to chemotherapy and tumor metastasis. Consistently, ADAM8 is a critical driver of growth and spread of many aggressive cancers. Adecto’s initial focus is on triple-negative breast cancer with a plan to expand to other oncology indications in the future. The firm's approach is based on the discovery that two distinct extracellular portions of ADAM8 drive its multiple cancer promoting functions and must therefore be both inactivated for an effective therapeutic response. Using a proprietary method, Adecto Pharmaceuticals has generated highly specific dual antagonist monoclonal anti-ADAM8 antibodies that simultaneously inhibit these two domains. Two top dual inhibitors, termed ADP2 and ADP13, are currently advancing through preclinical development. Development of a diagnostic product is also in the pipeline.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Gail E Sonenshein -- Founder and President

  Nora Mineva -- Chief Scientific Officer

  Mathilde Romagnoli -- Translational Research Scientist

Company News

There are no news available.